personalized cancer neoantigen vaccine GAd-PEV

A personalized neoantigen priming vaccine comprised of a great ape (gorilla) adenoviral (GAd) vector encoding numerous patient-specific tumor neoantigens, which are identified based on patient-specific tumor mutations obtained from the individual’s tumor, with potential immunostimulatory and antineoplastic activities. The neoantigens are the same as the ones in the booster vaccine MVA-PEV. Upon administration of the priming vaccine personalized cancer neoantigen vaccine GAd-PEV, the neoantigens are expressed and presented to the immune system. This may induce CD8+ and CD4+ neoantigen-specific T-cell responses against the patient’s tumor cells expressing the neoantigens.